Centessa Pharmaceuticals (NASDAQ:CNTA) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Centessa Pharmaceuticals (NASDAQ:CNTA) issued its earnings results on Tuesday. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05, Zacks reports.

Centessa Pharmaceuticals Stock Up 6.4 %

Shares of NASDAQ:CNTA opened at $18.08 on Thursday. The firm has a market capitalization of $2.05 billion, a PE ratio of -11.82 and a beta of 1.47. The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29. Centessa Pharmaceuticals has a 52-week low of $5.58 and a 52-week high of $18.74. The firm has a fifty day moving average of $15.81 and a 200 day moving average of $12.03.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, CEO Saurabh Saha sold 4,169 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total value of $51,362.08. Following the completion of the transaction, the chief executive officer now directly owns 827,755 shares in the company, valued at approximately $10,197,941.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 25,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $15.00, for a total transaction of $375,000.00. Following the completion of the sale, the insider now directly owns 223,369 shares in the company, valued at $3,350,535. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the transaction, the chief executive officer now directly owns 827,755 shares in the company, valued at $10,197,941.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 325,031 shares of company stock worth $5,213,043 over the last 90 days. Corporate insiders own 11.59% of the company’s stock.

Analyst Ratings Changes

CNTA has been the subject of a number of analyst reports. BMO Capital Markets raised their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Oppenheimer restated an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Guggenheim upped their price target on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Jefferies Financial Group lifted their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Finally, Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $25.17.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.